Qiagen steadies after recent pullback, shares tracked on NYSE and Xetra
27.06.2026 - 10:05:43 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-27, 10:05.
Qiagen N.V. (NL0012169213) trades on the NYSE under the ticker QGEN and in Frankfurt on Xetra, giving the diagnostics specialist broad access to US and European capital markets. The shares recently slipped on Xetra to around 34 euros and closed on the NYSE at 39.36 US dollars on June 26, according to exchange data and MarketBeat.
What recent prices show
On the NYSE, Qiagen shares closed at 39.36 US dollars on June 26, 2026, with a modest 1.07 percent gain on the day as reported by MarketBeat price data. After-hours trading saw the line at 39.00 dollars, indicating a slightly softer tone into the evening session.
On Xetra, Qiagen shares most recently changed hands at roughly 34.32 euros on June 26 with a daily decline of about 0.59 percent, according to German trading platforms citing Deutsche Börse data. This places the German line at a typical discount to the US listing, reflecting currency effects and local liquidity.
How analysts view Qiagen
Analyst coverage continues to focus on Qiagen’s position in molecular diagnostics and sample preparation, areas that large peers such as Roche and Thermo Fisher Scientific also target. Consensus data on several platforms still describe a predominantly positive long-term stance on QGEN, with a majority of published ratings in the Buy or Outperform range, although exact distributions vary by source such as MarketWatch analyst estimates.
Price targets compiled by these services typically sit above the current NYSE level, indicating that many covering banks see upside potential over a multi-quarter horizon. The range of targets often spans from the mid-40s to low-50s in US dollars, underlining differing views on growth in testing volumes, instrument placements and consumables demand.
All news and price data on the Qiagen shares
Further disclosures, historical prices and corporate publications for Qiagen can be found in the dedicated topic area and via the company’s own investor relations pages.
The business behind Qiagen
Qiagen generates most of its revenue from consumables and instruments for molecular diagnostics and life science research, spanning sample collection, nucleic acid extraction, assay set-ups and analysis. Flagship product families include QIAprep sample preparation solutions and QIAsymphony automation platforms used in laboratory workflows worldwide.
Where the stock trades now
The Qiagen N.V. shares (NL0012169213) traded on June 26, 2026 at around 39.36 US dollars on the NYSE and 34.32 euros on Xetra, reflecting the dual-listing structure between the US and German markets.
Qiagen N.V. at a glance
- Company: Qiagen N.V.
- ISIN: NL0012169213
- WKN: A2DKCH
- Ticker: QGEN
- Trading venue: NYSE / Xetra
- Price (as of 2026-06-26, 21:00): 39.36 USD / 34.32 EUR
- Market cap: approximately 8.8 billion USD (as of 2026-06-26)
- Sector / industry: Health Care - Life Sciences Tools & Services
- Index membership: Typically included in major health care and mid-cap indices; QGEN is a component of some global and regional benchmarks.
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation or an invitation to buy or sell securities. Investors should conduct their own research and, where appropriate, consult a qualified financial advisor before making investment decisions.
